Clinical Trial

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Study Description

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent it.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Acetylsalicylic acid

81 mg PO daily or 325 mg PO daily

Placebo

One tablet PO daily

Additional Information

Official Study Title

A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women With BRCA 1/2 Mutations (STICs and STONEs)

Clinical Trial ID

NCT03480776

ParticipAid ID

ZdP06d